An open-label phase 1/2a study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Rathkopf, D. E.; Saleh, M. N.; Tsai, F. Y. C.; Rosen, L. S.; Adams, B. J.; Liu, L.; Theuer, C. P.; Freddo, J. L.; Agarwal, N. |
| Abstract Title: | An open-label phase 1/2a study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 2018 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2018 Feb 8-10 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-02-20 |
| Language: | English |
| ACCESSION: | WOS:000436179500397 |
| DOI: | 10.1200/JCO.2018.36.6_suppl.TPS403 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS403 -- Source: Wos |
